Vveo3.Sa

The company's capital structure is characterized by a high debt-to-equity ratio of 2.0, indicating a significant reliance on debt financing. The liquidity position is moderate, with a current ratio of 1.33 and cash and equivalents amounting to 428.72 million BRL. The price-to-book ratio of 0.22 suggests that the company's market value is significantly lower than its book value, which may indicate undervaluation or underlying asset issues.

In terms of profitability, the company's return on equity (ROE) is 0.94%, and return on assets (ROA) is 0.20%, both of which are below the industry median for pharmaceutical companies. The operating margin is 4.6%, and the net profit margin is 0.16%, indicating that the company is generating modest profits relative to its revenue. These metrics suggest that the company is underperforming compared to its peers in terms of profitability and asset utilization.

The company's revenue is primarily concentrated in a single geographic region, with no disclosed segment breakdown. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The absence of detailed segment data makes it difficult to assess the company's performance across different product lines or markets.

The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial data. The operating cash flow is 276.58 million BRL, and the free cash flow is 183.09 million BRL, indicating that the company is generating positive cash flow from operations. However, the capital expenditure of -165.53 million BRL suggests that the company is not investing heavily in new projects or infrastructure, which may limit its long-term growth potential.

The company faces several risk factors, including a high debt-to-equity ratio and a negative net cash position after subtracting total debt. The liquidity risk is moderate, and the dilution risk is low, with no significant dilution potential reported. The company's financial leverage and cash flow position may pose challenges in maintaining financial stability, especially in a volatile market environment.

Recent events and filings indicate that the company has not issued any new shares or raised additional capital in the recent period. The analyst estimates suggest a mean price target of 1.46 BRL, with a median price target of 1.40 BRL, indicating a generally neutral outlook from analysts. The company's stock is currently trading at 1.35 BRL, which is below the mean price target, suggesting potential for moderate appreciation.